In:
Hepatology Research, Wiley, Vol. 51, No. 6 ( 2021-06), p. 641-651
Abstract:
This study aimed to analyze the effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors on the indexes of liver fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease, and also to observe the effects on liver enzymes and liver fat. Methods This meta‐analysis was performed using RevMan 5.3 statistical software. Results SGLT2 inhibitors could significantly reduce the level of hepatic fibrosis index: fibrosis‐4 (mean difference [MD] 0.25, 95% CI −0.39 to −0.11, p = 0.0007); serum type Ⅳ collagen 7s (MD 0.32, 95% CI −0.59 to −0.04, p = 0.02); and ferritin (MD 26.7, 95% CI 50.64, 2.76, p = 0.03). SGLT2 inhibitors could significantly reduce the level of liver enzymes: alanine aminotransferase (MD 3.49, 95% CI −5.1 to 1.58, p 〈 0.0001); aspartate aminotransferase (MD 3.64, 95% CI −5.10 to −2.18, p 〈 0.00001); and glutamate aminotransferase (MD 7.13, 95% CI −12.95 to −1.32, p = 0.02). SGLT2 inhibitors could significantly reduce the level of liver fat: liver‐to‐spleen attenuation ratio (MD 0.16, 95% CI 0.10–0.22, p 〈 0.00001); magnetic resonance imaging proton density fat fraction (MD 1.97, 95% CI −3.49 to −0.45, p = 0.01); liver controlled attenuation parameter (MD 0.29, 95% CI −26.95 to −13.64, p 〈 0.00001); liver fat score (MD 0.55, 95% CI 1.04 to −0.05, p = 0.03); and liver fat index (MD 11.21, 95% CI −16.53 to −5.89, p 〈 0.0001). Conclusion SGLT2 inhibitors could improve liver fibrosis, liver enzymes, liver fat, and metabolic indexes in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease.
Type of Medium:
Online Resource
ISSN:
1386-6346
,
1872-034X
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
2006439-1
Permalink